TY - JOUR
T1 - Efficacy of omalizumab in chronic spontaneous urticaria refractory to conventional therapy: Analysis of 110 patients in real-life practice
AU - Labrador-Horrillo, Moises
AU - Valero, Antonio
AU - Velasco, Manuel
AU - Jáuregui, Ignacio
AU - Sastre, Joaquin
AU - Bartra, Joan
AU - Silvestre, Juan Francisco
AU - Ortiz De Frutos, Javier
AU - Gimenez-Arnau, Ana
AU - Ferrer, Marta
PY - 2013/9/1
Y1 - 2013/9/1
N2 - Objective: To collect data on the efficacy and safety of omalizumab in 110 patients from 9 Spanish hospitals suffering from chronic spontaneous urticaria (CSU) refractory to conventional treatment. Methods: A retrospective, descriptive analysis was performed, showing the data of 110 patients suffering from refractory CSU who received omalizumab as an off-label treatment in 9 Spanish hospitals from October 2009 to September 2012. Results: Ninety (81.8%) patients exhibited a complete or significant response, 12 (10.9%) had partial response, and 8 (7.2%) showed no response. Sixty-six (60%) patients were able to stop all concomitant medications, remaining asymptomatic treated with omalizumab alone. No serious adverse events were reported. Conclusions: Omalizumab shows excellent efficacy and safety profile in a large series of CSU patients in real-life practice. This drug will contribute to settle the debt with CSU patients contributing to restore their quality of life. © Informa UK, Ltd.
AB - Objective: To collect data on the efficacy and safety of omalizumab in 110 patients from 9 Spanish hospitals suffering from chronic spontaneous urticaria (CSU) refractory to conventional treatment. Methods: A retrospective, descriptive analysis was performed, showing the data of 110 patients suffering from refractory CSU who received omalizumab as an off-label treatment in 9 Spanish hospitals from October 2009 to September 2012. Results: Ninety (81.8%) patients exhibited a complete or significant response, 12 (10.9%) had partial response, and 8 (7.2%) showed no response. Sixty-six (60%) patients were able to stop all concomitant medications, remaining asymptomatic treated with omalizumab alone. No serious adverse events were reported. Conclusions: Omalizumab shows excellent efficacy and safety profile in a large series of CSU patients in real-life practice. This drug will contribute to settle the debt with CSU patients contributing to restore their quality of life. © Informa UK, Ltd.
KW - Chronic spontaneous urticaria
KW - Chronic urticaria
KW - CSU
KW - Omalizumab
U2 - 10.1517/14712598.2013.822484
DO - 10.1517/14712598.2013.822484
M3 - Article
SN - 1471-2598
VL - 13
SP - 1225
EP - 1228
JO - Expert Opinion on Biological Therapy
JF - Expert Opinion on Biological Therapy
IS - 9
ER -